News & Events
- Seres Therapeutics Expands Executive Team with Appointments of David S. Ege, Ph.D., as Chief Technology Officer and Jayne M. Gansler as Chief People Officer
- Seres Therapeutics to Present SER-109 Phase 3 ECOSPOR III Study Results at American College of Gastroenterology Annual Scientific Meeting
- Vedanta Biosciences Announces Additional Pharmacokinetics Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020
- Vedanta Biosciences Awarded Up to $76.9 Million Including $7.4 Million Upfront from BARDA to Advance the Development of VE303, a Defined Bacterial Consortium for Prevention of C. difficile Infection in High-Risk Patients
- Seres Therapeutics to Present at the Jefferies Next Generation IBD Therapeutics Summit
- Vedanta Biosciences Announces the Appointment of Jeffrey Silber, M.D. as Chief Medical Officer
- Seres Therapeutics to Present at Upcoming Investor Conferences
- Seres Therapeutics Announces U.S. Food and Drug Administration Correspondence Following Positive SER-109 Phase 3 Study Results
- Seres Therapeutics, Inc. Announces Closing of Public Offerings of 12,075,000 Shares of Common Stock
- Seres Therapeutics, Inc. Announces Pricing of Public Offering of 10,500,000 Shares of Common Stock
- Seres Therapeutics Announces Positive Topline Results from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. difficile Infection
- Seres Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
- Seres Therapeutics Appoints Terri Young, Ph.D., R.Ph., Experienced Commercial Leader, as Executive Vice President, Chief Commercial and Strategy Officer
- Vedanta Biosciences Announces Positive Topline Data from Two Phase 1 Studies of VE202, a Rationally Defined Bacterial Consortium Being Advanced for Inflammatory Bowel Diseases (IBD)
- Seres Therapeutics to Present at the Goldman Sachs 41st Annual Global Virtual Healthcare Conference